Kura Oncology (KURA) Convertible Debt (2014)

Kura Oncology (KURA) posted quarterly Convertible Debt of $500000.0 for Q4 2014.

Kura Oncology (KURA) Convertible Debt (2014) Analysis & Trends

Kura Oncology (KURA) has reported Convertible Debt for 1 consecutive years, with $500000.0 the latest figure, recorded in Q4 2014.

  • In Q4 2014, Convertible Debt changed N/A year-over-year to $500000.0; the TTM figure through Dec 2014 stood at $500000.0 (changed N/A YoY), while the FY2014 annual figure was $500000.0, changed N/A from the prior year.
  • Convertible Debt steadied at $500000.0 in Q4 2014 per KURA's latest filing.
  • Across five years, Convertible Debt topped out at $500000.0 in Q4 2014 and bottomed at $500000.0 in Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Kura Oncology 966.11 Mn 966.11 Mn 20.63 Mn

Historic Data

Download Data
DateValue
Dec 31, 2014 500,000.00